Amarin Corporation plc

Company purpose

• Pharmaceutical company focused on commercialization and development of therapeutics to improve cardiovascular health and reduce cardiovascular risk.

Core marketed products

• VASCEPA® (icosapent ethyl)
  • U.S. indication: adjunct to maximally tolerated statin therapy to reduce cardiovascular risk in adults with elevated triglycerides and either established cardiovascular disease or diabetes with additional risk factors.
  • U.S. launch: commercial since 2013; REDUCE-IT outcomes supported expanded cardiovascular risk reduction labeling in 2019.
• VAZKEPA® (European brand; same active ingredient as VASCEPA)
  • Approved in the European Union for high-risk, statin-treated adults with elevated triglycerides and cardiovascular risk; also approved in the U.K. (MHRA).
• The company operates VASCEPA/VAZKEPA as a single branded franchise across multiple markets, with regional partners and licensing arrangements for non-U.S. regions.

Global business model and partnerships

United States

• Primary market with a limited number of major wholesalers and distributors.
• Three top customers accounted for 28%, 27% and 31% of 2025 U.S. gross product sales; 23%, 17% and 43% of gross accounts receivable for the same period.

Europe and Rest of World (RoW)

• Key partners and territories:
  • Recordati: exclusive license to develop and commercialize VAZKEPA in 59 European countries (the Recordati Territory). In June 2025 Amarin licensed the Recordati Territory to Recordati and will receive sales-based milestones (up to $150 million, paid once per event) and ongoing royalties on net sales.
  • CSL Seqirus: Australia and New Zealand (pricing, reimbursement, distribution, commercialization).
  • HLS Therapeutics: Canada (registration, commercialization).
  • Biologix FZCo: Middle East and North Africa (registration, commercialization).
  • Eddingpharm: Mainland China and Hong Kong (development and commercialization).
  • Lotus Pharmaceuticals: Southeast Asia (registration, distribution).
  • Neopharm (Israel) 1996 Ltd.: Israel (distribution, regulatory).
  • Vianex S.A.: Greece (import, registration, distribution for VAZKEPA).

RoW pipeline and activity

• Agreements and activities in 22 countries with approvals or ongoing regulatory submissions in 17 countries outside U.S./EMA regions as of the filing.
• Pre-launch and launch activities proceed in partner markets as approvals occur.

Manufacturing and supply

• No internal manufacturing; relies on contract manufacturers for API, encapsulation, packaging and logistics.
• Diversified supplier base and maintained inventory to support U.S. and international needs.

Corporate actions and restructuring

• Global Restructuring Plan announced June 2025 to align with the exclusive Recordati license and streamline European operations.
• Expected annual cost savings: approximately $70 million.
• Resulted in a reduction of commercial roles in Europe and ongoing adjustments to global operations.

Financial snapshot (selected metrics as of 12/31/2025)

• Employees: approximately 80 full-time employees across six countries.
  • U.S.: about 60% of employees; Europe: about 40%.
• Inventory: $195.9 million total; roughly 50% approved for use in North America.
• Profitability and capital:
  • Net losses: 2025 net loss of approximately $38.8 million; 2024 net loss of approximately $82.2 million; 2023 net loss of approximately $59.1 million.
  • Accumulated deficit: about $1.7 billion.
• Revenue mix:
  • The majority of revenue is derived from VASCEPA sales.

Growth and investment

• Ongoing efforts to expand the international footprint through partner networks and geographic licenses.
• Continued emphasis on validating and extending REDUCE-IT–era data to support broader cardiovascular risk reduction use.

Intellectual property

• Patents and patent applications related to VASCEPA/VAZKEPA and its uses, with U.S. and international filings across several patent families.
• Core products (EPA-only, DHA-free) are protected by a portfolio Amarin intends to defend against generic competition, with several years of potential market protection in key regions.

Business focus summary

• Amarin concentrates on expanding the use and reach of VASCEPA/VAZKEPA to reduce cardiovascular events in high-risk patients with elevated triglycerides, based on REDUCE-IT data.
• Growth is driven by U.S. sales and international expansion via licensing and partnerships, supported by a global supply chain of contract manufacturers.
• Strategic actions in 2025 include the global restructuring tied to the Recordati license, potential milestone and royalty revenue from the Recordati Territory, and efforts to secure pricing and reimbursement in non-U.S. markets.